DHHS → node
On January 1, 2023, MaineCare will add coverage for donor breast milk (CPT code T2101 - Human breast milk processing, storage, and distribution) under Section 90, Physician Services, and Section 45, Hospital Services, in accordance with Maine P.L. 2021, Ch.
The Food and Drug Administration (FDA) announced on November 30, 2022, that bebtelovimab, 175mg, no longer has Emergency Use Authorization (EAU).
|
Eli Lilly EUA Monoclonal Antibody COVID-19 Infusion Treatment-bebtelovimab, 175mg |
||
|
Correction: Application Fee for 2023 Reminder, CR 114074Please note the application fee adjustment is for CY 2023, not 2022, as published in a previous message. Electronic Visit Verification (EVV) Trainings and ForumsThe federal deadline to implement the EVV requirements for Home Health providers delivering services under Section 40 and Hospice providers delivering services under Section 43 is January 1, 2023. With these EVV deadlines quickly approaching, we continue to offer weekly provider and aggregator trainings and forums. All trainings and forums are online via Microsoft Teams. Application Fee for 2022 Reminder, CR 114074Effective January 1, 2023, in accordance with the Centers for Medicare & Medicaid Services (CMS) application fee requirements, MaineCare’s provider enrollment application fee will increase to $688 per enrollment application. This increase will apply to new, reactivating, or revalidating providers, or when adding new service locations to an existing enrollment. You can pay the application fee by credit or debit card at the time of application submission. Section 30, Family Planning Services – Reimbursement Model and Rate Study Kickoff MeetingAs previously shared in our November 17, 2022, bulletin, the Department initiated a rate determination for Section 30, Family Planning Services. As a result of that process, we are now conducting a rate study. MaineCare Rate System ReformOur GoalTo provide a clear and transparent process for MaineCare rate determinations, with opportunities for robust participation from all interested stakeholders. We will be updating this page with important dates and progress made on past, current, and future rate determination work. Please check in often, as this site is a work in progress. (Corrected Effective Date) Pfizer and Moderna COVID-19 Bivalent Vaccine Authorized for use in individuals aged Six Months to Five YearsThis message corrects an earlier message that listed an incorrect to the effective date in the table. All correct dates are now listed. | ||